Alpha Tau Medical Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DRTS research report →
About the company
Alpha Tau Medical Ltd. , a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors.
- CEO
- Uzi Sofer
- IPO
- 2021
- Employees
- 118
- HQ
- Jerusalem, IL
Price Chart
- Market Cap
- $1.20B
- P/E
- -19.75
- P/S
- 0.00
- P/B
- 17.11
- EV/EBITDA
- -26.73
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -73.23%
- ROIC
- -46.51%
- Revenue
- $0 · 0.00%
- Net Income
- $-42,627,000 · -34.26%
- EPS
- $-0.53 · -17.78%
- Op Income
- $-42,288,000
- FCF YoY
- -48.75%
- 52W High
- $13.23
- 52W Low
- $2.87
- 50D MA
- $9.67
- 200D MA
- $6.67
- Beta
- 1.17
- Avg Volume
- 821.62K
Get TickerSpark's AI analysis on DRTS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | Levy Raphi | other | 2,127 |
| Jul 1, 26 | Levy Raphi | sell | 2,127 |
| Jun 30, 26 | Levy Raphi | sell | 20,000 |
| Jun 25, 26 | Levy Raphi | sell | 4,222 |
| Jun 25, 26 | Levy Raphi | sell | 15,778 |
| Jun 23, 26 | Levy Raphi | sell | 15,000 |
| Jun 23, 26 | Levy Raphi | sell | 2,500 |
| Jun 3, 26 | Levy Raphi | sell | 17,500 |
| Jun 3, 26 | Levy Raphi | sell | 15,000 |
| Mar 18, 26 | Avruch Michael | other | 0 |
Our DRTS coverage
Recent articles, reports, and earnings notes.
No research on DRTS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DRTS report →Similar companies
Peers in the same neighborhood.